Core Viewpoint - The company held its fifth extraordinary general meeting of shareholders on November 17, 2025, where several important resolutions were passed, including the cancellation of the supervisory board and amendments to the company's articles of association [2][4][6]. Group 1: Meeting Details - The meeting was attended by 1,332 shareholders, representing a total of 79,414,969 voting shares, which accounts for 37.86% of the company's total voting shares [2]. - The meeting was chaired by Director Zhou Zhi due to the absence of Chairman Chen Xue Min [3]. - Voting was conducted through a combination of on-site and online methods, complying with relevant laws and regulations [3]. Group 2: Resolutions Passed - The resolution to cancel the supervisory board and amend the articles of association was approved with 99.96% of votes in favor [5][6]. - Other governance-related resolutions, including the rules for shareholder meetings, board meetings, independent director work systems, related party transaction decision-making systems, external guarantee management systems, fundraising management methods, and remuneration management systems for directors and senior management, were also passed with high approval rates, generally above 99.95% [5][6]. Group 3: Project Update - The company’s wholly-owned subsidiary, Ganzhou Songhui Fluorine New Materials Co., Ltd., has completed the construction and installation of a project for producing 10,000 tons of boron trifluoride gas and 20,000 tons of boron trifluoride complexes, which has received approval for trial production [9]. - Boron trifluoride is primarily used in pharmaceuticals, semiconductors, nuclear power radiation protection, lithium batteries, solid-state battery additives, and high-end chip etching [9]. - The project is expected to enhance the company's product structure, create new profit growth points, and improve core competitiveness through resource integration and cost reduction [10].

Key Points - The article highlights significant announcements from various companies, including acquisitions, project investments, and share buybacks [1][2] Company Announcements - Zhenai Meijia has no asset restructuring plans for the next twelve months [1] - Geer Software's quantum-resistant encryption products are still in the standardization and pilot application phase, indicating a distance from large-scale commercialization [1] - Xianiao New Energy plans to invest 1.525 billion yuan to construct a project with an annual production capacity of 50,000 tons of high-performance battery materials [1] - Gao Neng Environment has won a contract for a waste-to-energy project in Thailand [1] - Wei Hua New Material intends to acquire 70% of He Yu Tai for 154 million yuan [1] - Zanyu Technology has completed a share buyback of 1.9751% of its shares [1][2] - Aibulu's actual controller plans to reduce his stake by no more than 3% [2] - Wantong Technology plans to raise no more than 920 million yuan through a private placement [2] - Huiyuan Communication aims to raise no more than 610 million yuan through a private placement [1][2]

证券日报网讯11月18日晚间，深圳新星（603978）发布公告称，截至本公告披露日，公司已完成回购， 实际回购公司股份161.74万股，占公司总股本的比例为0.77%。 ...

Core Viewpoint - Shenzhen New Star has completed a share buyback, acquiring 1.6174 million shares, which represents 0.77% of the total share capital, with a total expenditure of approximately RMB 30.01 million [1] Group 1: Share Buyback Details - The company has completed a buyback of 1.6174 million shares, accounting for 0.77% of its total share capital [1] - The highest buyback price was approximately RMB 39.47 per share, while the lowest was RMB 9.33 per share [1] - The total amount paid for the buyback was around RMB 30.01 million [1] Group 2: Revenue Composition - For the year 2024, the revenue composition of Shenzhen New Star is as follows: 96.09% from non-ferrous metal processing, 3.68% from new energy lithium battery materials, and 0.23% from other businesses [1] Group 3: Market Capitalization - As of the report, Shenzhen New Star has a market capitalization of RMB 7 billion [1]

格隆汇11月18日丨深圳新星(603978.SH)公布，截至本公告披露日，公司已完成回购，实际回购公司股 份161.74万股，占公司总股本的比例为0.77%，回购最高价为39.4665元/股、最低价为9.33元/股，已支付 的总金额为人民币3,000.1235万元（不含印花税、交易佣金等交易费用）。 ...

Group 1 - Shengxin Lithium Energy signed a framework agreement with Huayou Cobalt for the procurement of 221,400 tons of lithium salt products over five years [1] - Wehua New Materials' subsidiary plans to acquire 70% of He Yutai for 154 million yuan [1] - Xiamen Tungsten plans to invest 600 million yuan to establish a wholly-owned subsidiary for a project with an annual production capacity of 50,000 tons of high-performance battery materials [1][2] Group 2 - *ST Songfa's subsidiary signed a shipbuilding contract worth approximately 200-300 million USD for two VLCCs [3] - Hailianxun's stock will resume trading on November 19 after the end of the acquisition request period [5] - Yunnan Energy Investment obtained the development rights for a 25,000 kW wind power project [7] Group 3 - China Resources Double Crane's subsidiary received a drug registration certificate for Oxcarbazepine tablets [8] - Jincheng Pharmaceutical's subsidiary received a CEP certificate for glutathione raw materials [9] - Jinkong Electric plans to transfer 51% of Tongying Thermal Power to an affiliate for 266 million yuan [9] Group 4 - Clean Technology's subsidiary won a bid for a waste incineration power generation project in Thailand with a total investment of up to 4.27 million USD [12] - Tonglian Precision's shareholders set the transfer price for shares at 43.67 yuan each [13] - Hu Nong Commercial Bank's executives collectively purchased 259,100 shares of the company [13] Group 5 - Huatai Medical's subsidiary obtained a medical device registration certificate for polyethylene embolization microspheres [13] - Fosun Pharma's subsidiary's drug registration application was accepted by the National Medical Products Administration [13] - Xianhui Technology signed contracts worth 796 million yuan with multiple subsidiaries of CATL [15] Group 6 - Ningbo Fangzheng signed a strategic cooperation agreement with Huaxiang Qiyuan for the development of various robotic technologies [15] - Ruida Futures' vice president resigned for personal reasons [16] - Samsung Medical is expected to win contracts worth approximately 125 million yuan from the State Grid [17] Group 7 - Tianjin Pharmaceutical's injectable methylprednisolone sodium succinate received registration from Panama's Ministry of Health [19] - Yaxing Anchor Chain plans to invest up to 300 million yuan in a project for deep-sea floating equipment [20] - Zejing Pharmaceutical's clinical trial for ZG006 was approved by the National Medical Products Administration [21] Group 8 - Weiye Co., Ltd. won a bid for a project worth approximately 2.086 billion yuan [23] - Ruimao Tong plans to sell 8.5794 million repurchased shares [25] - Guangge Technology's shareholders plan to reduce their holdings by up to 3.99% [26] Group 9 - Hongsheng Development signed a debt restructuring contract for a total of 2 billion yuan [27][28] - Yatai Co., Ltd. plans to reduce its holdings by up to 1% [30] - Dexin Technology's shareholder plans to reduce its holdings by up to 1% [31] Group 10 - Yaji International's shareholder plans to reduce its holdings by up to 1% [33] - Shenzhen New Star's subsidiary received approval for trial production of a boron trifluoride project [35] - Shengyi Electronics plans to raise up to 2.6 billion yuan through a private placement [36]

证券代码：603978 证券简称：深圳新星 公告编号：2025-108 深圳市新星轻合金材料股份有限公司 关于股份回购实施结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/2/21，由实际控制人、董事长兼总经理陈学 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | | 敏先生提议 | | | | | | | 回购方案实施期限 | 年 2 月 11 月 日 | 2024 | 20 | 日~2025 | 年 | 19 | | 预计回购金额 | 3,000万元~6,000万元 | | | | | | | 回购价格上限 | 41元/股 | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | □用于转换公司可转债 | | | | | | | | □为维护公司价值及股东权益 | | | | | | | 实际回购股数 | 161.74万股 ...

Core Viewpoint - The company has successfully implemented a share repurchase plan proposed by its actual controller, chairman, and general manager, Chen Xueming [1] Group 1: Share Repurchase Details - The total number of shares repurchased is 1.6174 million, which accounts for 0.77% of the total share capital [1] - The total amount spent on the repurchase is 30.0012 million yuan [1] - The repurchase price range was between 9.33 yuan per share and 39.47 yuan per share [1] Group 2: Purpose of Repurchase - The repurchased shares will be used for employee stock ownership plans or equity incentives [1]

Group 1 - The PVDF concept sector experienced a decline of 3.53%, ranking among the top declines in the concept sector, with stocks like Putailai and Duofluoride hitting the daily limit down [1] - Major stocks within the PVDF concept, such as Duofluoride and Putailai, saw significant drops, with Duofluoride down by 9.99% and Putailai also down by 9.99% [2][3] - The PVDF concept sector faced a net outflow of 2.148 billion yuan, with 14 stocks experiencing net outflows, and 11 stocks seeing outflows exceeding 30 million yuan, led by Duofluoride with a net outflow of 1.436 billion yuan [2] Group 2 - Other concept sectors showed varied performance, with the Xiaohongshu concept rising by 3.16% and the sodium-ion battery concept declining by 3.76% [2] - The top net inflow stocks included Dongyangguang, Jinming Precision Machinery, and Shengjingwei, with net inflows of 33.5148 million yuan, 4.946 million yuan, and 254,300 yuan respectively [2][3] - The trading volume for Duofluoride was notably high, with a turnover rate of 20.77% alongside a significant net outflow of 1.436 billion yuan [2]

Core Points - Shenzhen Xinxing announced that its wholly-owned subsidiary, Ganzhou Songhui Fluorine New Materials Co., Ltd., has completed the main construction and equipment installation of a project with an annual production capacity of 10,000 tons of boron trifluoride gas and 20,000 tons of boron trifluoride complex [2] Group 1 - The project has passed expert review and received approval for trial production [2] - The project is now ready for trial production [2]